Good Morning Traders!
I believe the next round of billionaires will come out of the widespread legalization of marijuana.
In the meantime though (while lawmakers make up their minds), sections of Wall Street are crushing it and everybody from entrepreneur to trader is making bank. I have delivered a few medical marijuana winners over the last few months so I know there’s green to be made.
I hope you are ready to make some good cash because CBIS is ready to deliver on its gain potential. The company is coming off some exciting patent news.
Investors and traders were treated with news that the company in support of its CBN patent, has delivered a pure CBN compound to two research facilities in Europe where testing will establish the activity of CBN alone and in combination with other cannabinoids for treating anxiety, sleep disorders as well as a variety of neurological conditions including Alzheimer's disease.
CBIS is also pressing ahead with a joint operation to observe the effect of medical marijuana in patients in the Netherlands. The company is working with MEDIWIET, the largest European organization of patients who use medicinal cannabis-based treatments. So far more than 3,000 people have come in contact with MEDIWIET and that number is growing.
Now when you conduct your own due diligence you’ll see that CBIS is trading below .10 but don’t do like most traders and walk away. I think CBIS is a solid .50 play and it has a 12-month high of .30 to prove it has legs.
Further news about its progress and the wider growth in the medical marijuana space is going to turn this into a sweet company indeed.
Right now you have the chance of making some cabbage from its gain potential for about .09 a share.
It’s a no-brainer buy so get your due diligence going as soon as possible.
Investor Highlights
CBIS shows an established uptrend in its trading chart and recent rallies of up to 10% confirm that traders are bullish in the play.
RSI for CBIS is a very attractive 53. The added bonus and catalyst for traders is that since December more than 228% has been added to lower levels.
CBIS recently announced that it is working closely with Mediwiet and its founder, Mr. Wernard Bruining, on the building blocks necessary for the launch of the Clinical Observational Study, as previously announced.
CBIS is also moving aggressively to gets CBN patent approved and recently delivered pure CBN compound to two research facilities in Europe where testing establish the activity of CBN alone and in combination with other cannabinoids.
CBIS is also in discussions with a leading biotech company to oversee clinical trials in Columbia, a move that will see heavy research and development of a cannabis based medicine to treat skin cancer.
About CBIS
CBIS (Cannabis Science, Inc.) engages in the development, production, and commercialization of phytocannabinoid-based pharmaceutical products.
CBIS primarily focuses on developing medications to treat autism, blood pressure, cancer and cancer side effects, HIV, and other illnesses, including general health maintenance.
CBIS has a license agreement with Apothecary Genetics Investments LLC. to produce various brand formulations for the California medical cannabis market.
CBIS is based in Colorado Springs, Colorado.
Senate Says DEA Can No Longer Target Medical Marijuana
Reflecting growing national acceptance of weed, a coalition of House members from both parties voted early Friday to restrict the Drug Enforcement Administration from using funds to go after medical marijuana operations that are legal in state laws.
The Senate will likely consider its own appropriations bill for the DEA and the House amendment would have to survive a joint conference before it could go into effect.
Rohrabacher said on the House floor that the amendment should be a no-brainer for conservatives and argued passionately against allowing the federal government to interfere with any doctor-patient relationship.
"Some people are suffering, and if a doctor feels that he needs to prescribe something to alleviate that suffering, it is immoral for this government to get in the way," Rohrabacher said.
Harris, a doctor and politician who voted against the amendment, insisted that there were no medical benefits to marijuana and that medical marijuana laws were a step toward legalizing recreational pot.
"It's the camel's nose under the tent," said Harris. He cited piece of anti-marijuana propaganda published by the DEA this month that claimed medical marijuana was just "a means to an end." The taxpayer-funded report uses scary quotes around the word "medical."
"I don't think we should accept at all that this is history in the making," said Fleming, who said earlier this month that it wasn't realistic to make alcohol illegal either, citing the failed amendment.
Broun said there were "very valid medical reasons" to use marijuana extracts or products. "It's less dangerous than some narcotics that doctors prescribe all over this country," Broun said. He said medical marijuana was a states' rights issue and Congress needed to "reserve the states’ powers under the Constitution."
"The conflicting nature of state and federal marijuana laws has created an untenable situation," Blumenauer said prior to the debate. "It's time we take the federal government out of the equation so medical marijuana business owners operating under state law aren't living in constant fear of having their doors kicked down in the middle of the night."
Under the Obama administration, the DEA and many U.S. attorneys raided marijuana dispensaries that complied with state laws. The DEA still classifies marijuana as a substance with no accepted medical use, and the agency has engaged in a public relations campaign to diminish medical benefits.
Currently, 22 states and the District of Columbia legalized marijuana for medical use. Five other states, Alabama, Kentucky, Mississippi, Utah, and Wisconsin, have legalized certain cannabis oils to treat epilepsy. There are other medical benefits to marijuana.
Thursday’s vote reflects changing public sentiment toward the government's failed war on drugs. A recent Pew survey found that 67 percent of Americans support drug policies that focus on providing treatment rather than arrest and jail time. An overwhelming majority of Americans also support the legalization of marijuana for medical purposes at the very least. A recent poll found 86 percent think doctors should be able to prescribe marijuana to seriously ill patients.
Recent Developments
Cannabis Science Cheers Dr. Oz on Becoming a Vocal Supporter of Medical Marijuana on The Larry King Live Show
On the Heels of Dr. Sanjay Gupta, Dr. Oz Comes Out to Support Medicinal Marijuana Use
COLORADO SPRINGS, Colo., May 27, 2014 /PRNewswire/ -- Cannabis Science, Inc. (CBIS), a U.S. Company specializing in the development of cannabis based medicine is glad to see a new milestone has been reached with Dr. Oz announcing on The Larry King Live show that his view has changed about medical marijuana use.
During an interview on Monday, May 12th, 2014, celebrity doctor Dr. Mehmet Oz, spoke with Larry King about his new perspective on the use of marijuana, particularly medical marijuana use.
Dr. Oz explains, "I grew up like most of my generation believing that marijuana was something (_____) was throwing at Americans…but I think most of us have come around to believe that marijuana is hugely beneficial when used correctly for medicinal purposes." Because smoking produces a psychoactive effect, however, Dr. Oz does warn against repeated recreational use, "...we pervert its use sometimes and I don't think it should be widely used, certainly not by kids because it creates a dependence that is unhealthy in any setting. But it absolutely should be widely available in America (for medical use)."
Read more about Dr. Oz on Larry King and watch a clip of the show at either of the following links:
http://www.huffingtonpost.com/2014/05/14/dr-oz-medical-marijuana_n_5324393.html
Dr. Oz is a cardiothoracic surgeon and teaching professor at Columbia University. He became famous as a regular guest on The Oprah Show but eventually went on to host his own successful American syndicated television talk, The Dr. Oz Show. It debuted in the fall of 2009 and it is now in its fifth season.
The senate is saying yes, Dr. Oz is saying yes so to say the tide has shifted towards widespread legalization would be understating things. All of America will be green in a matter of years and CBIS will be one of the companies reaping massively from this inevitability.
.09 a share is all you need to move on CBIS right now so don’t let this trading gem slip away from you.
To learn more about CBIS please visit their website http://www.cannabisscience.com/
